Roche Signs Agreements With Ortho-Clinical Diagnostics and Novartis
Posted on: Thursday, 15 November 2007, 06:00 CST
Roche has announced licensing and settlement agreements with Ortho-Clinical Diagnostics and Novartis Vaccines and Diagnostics in the field of hepatitis C virus diagnostics.
Under the terms of the licensing agreement, Ortho-Clinical Diagnostics and Novartis Vaccines and Diagnostics granted Roche Diagnostics a worldwide royalty-bearing license under their broad patent portfolio for hepatitis C virus (HCV) in the field of immunodiagnostics. The agreement also includes cross-licensing of patents owned by Roche Diagnostics. They further agreed to settle all litigation related to the licensed patents.
HCV represents a wide-spread hepatitis virus which frequently results in chronic liver disease and represents a major cause of death through the development of liver cirrhosis and liver cancer. HCV antibody tests are used for the primary diagnosis of hepatitis C virus infection in patients with suspected liver disease.
Dirk Ehlers, head of Roche Professional Diagnostics said: "We are pleased to have reached an agreement that provides Roche Diagnostics worldwide access to HCV immunoassays. This agreement will strengthen Roche's position in infectious disease diagnostics and will drive further growth of our immunoassay business worldwide."
Source: Datamonitor
Related Articles
- Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
- Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
- Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
- Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
- Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
- Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
- New Clinical Data Support Broad Profile for Telaprevir in Patients With Genotype 1 Hepatitis C Virus (HCV) Infection
- Presidio Pharmaceuticals Receives Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
- Valopicitabine (NM283) Combined With Pegylated Interferon Demonstrated Significantly Greater Suppression of Hepatitis C Virus (HCV) Replication in Treatment-Refractory Patients Compared to Retreatment With Ribavirin Plus Pegylated Interferon
- Worldwide Biotech & Pharmaceutical Obtains the China Patent Golden Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro By Cell Culture'
User Comments (0)

RSS Feeds